These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 29963042)

  • 1. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
    Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
    Front Immunol; 2018; 9():1282. PubMed ID: 29963042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
    Zingoni A; Vulpis E; Cecere F; Amendola MG; Fuerst D; Saribekyan T; Achour A; Sandalova T; Nardone I; Peri A; Soriani A; Fionda C; Mariggiò E; Petrucci MT; Ricciardi MR; Mytilineos J; Cippitelli M; Cerboni C; Santoni A
    Front Immunol; 2018; 9():926. PubMed ID: 29765374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Concentrations of Circulating Soluble MHC Class I-Related Chain A (sMICA) and sMICB and Modulation of Plasma Membrane MICA Expression: Potential Mechanisms and Correlation With Natural Killer Cell Activity in Systemic Lupus Erythematosus.
    Hervier B; Ribon M; Tarantino N; Mussard J; Breckler M; Vieillard V; Amoura Z; Steinle A; Klein R; Kötter I; Decker P
    Front Immunol; 2021; 12():633658. PubMed ID: 34012432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Umbilical cord blood plasma contains soluble NKG2D ligands that mediate loss of natural killer cell function and cytotoxicity.
    Cox ST; Laza-Briviesca R; Pearson H; Soria B; Gibson D; Gomez S; Madrigal JA; Saudemont A
    Eur J Immunol; 2015 Aug; 45(8):2324-34. PubMed ID: 25991034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered NK-cell compartment and dysfunctional NKG2D/NKG2D-ligand axis in patients with ataxia-telangiectasia.
    Desimio MG; Finocchi A; Di Matteo G; Di Cesare S; Giancotta C; Conti F; Chessa L; Piane M; Montin D; Dellepiane M; Rossi P; Cancrini C; Doria M
    Clin Immunol; 2021 Sep; 230():108802. PubMed ID: 34298181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
    Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
    Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversity and characterization of polymorphic 5' promoter haplotypes of MICA and MICB genes.
    Cox ST; Madrigal JA; Saudemont A
    Tissue Antigens; 2014 Sep; 84(3):293-303. PubMed ID: 24962621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding of the NKG2D ligand MICA.
    Isernhagen A; Schilling D; Monecke S; Shah P; Elsner L; Walter L; Multhoff G; Dressel R
    Immunogenetics; 2016 Feb; 68(2):109-23. PubMed ID: 26585323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and abscission of activated receptors and their ligands on/from NK cells in peripheral blood of patients with acute leukemia].
    Fang XC; Liu HL; Sun ZM; Gui L; Geng LQ; Wang XB; Zhou M; Wang ZY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):436-40. PubMed ID: 20416183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
    Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
    Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
    Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
    J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
    Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
    BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
    Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
    Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Variability of Human Cytomegalovirus Clinical Isolates Correlates With Altered Expression of Natural Killer Cell-Activating Ligands and IFN-γ.
    Galitska G; Coscia A; Forni D; Steinbrueck L; De Meo S; Biolatti M; De Andrea M; Cagliani R; Leone A; Bertino E; Schulz T; Santoni A; Landolfo S; Sironi M; Cerboni C; Dell'Oste V
    Front Immunol; 2021; 12():532484. PubMed ID: 33897679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
    Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.
    Machuldova A; Holubova M; Caputo VS; Cedikova M; Jindra P; Houdova L; Pitule P
    Front Immunol; 2021; 12():651751. PubMed ID: 33868289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation.
    Isernhagen A; Malzahn D; Viktorova E; Elsner L; Monecke S; von Bonin F; Kilisch M; Wermuth JM; Walther N; Balavarca Y; Stahl-Hennig C; Engelke M; Walter L; Bickeböller H; Kube D; Wulf G; Dressel R
    EMBO Mol Med; 2015 Nov; 7(11):1480-502. PubMed ID: 26483398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
    Sauer M; Schuldner M; Hoffmann N; Cetintas A; Reiners KS; Shatnyeva O; Hallek M; Hansen HP; Gasser S; von Strandmann EP
    Oncogene; 2017 Feb; 36(7):933-941. PubMed ID: 27477692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.
    Salih HR; Antropius H; Gieseke F; Lutz SZ; Kanz L; Rammensee HG; Steinle A
    Blood; 2003 Aug; 102(4):1389-96. PubMed ID: 12714493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.